Goldman Sachs’s Corbus Pharmaceuticals CRBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $590K | Sell |
62,863
-30,248
| -32% | -$286K | ﹤0.01% | 5596 |
|
|
2026
Q1 | $874K | Buy |
93,111
+45,673
| +96% | +$385K | ﹤0.01% | 5181 |
|
|
2025
Q4 | $386K | Buy |
47,438
+14,086
| +42% | +$174K | ﹤0.01% | 5753 |
|
|
2025
Q3 | $422K | Sell |
33,352
-10,322
| -24% | -$98.2K | ﹤0.01% | 5595 |
|
|
2025
Q2 | $301K | Sell |
43,674
-14,262
| -25% | -$104K | ﹤0.01% | 5442 |
|
|
2025
Q1 | $308K | Buy |
57,936
+762
| +1% | +$6.73K | ﹤0.01% | 5445 |
|
|
2024
Q4 | $675K | Buy |
57,174
+7,754
| +16% | +$130K | ﹤0.01% | 5070 |
|
|
2024
Q3 | $1.02M | Sell |
49,420
-11,108
| -18% | -$568K | ﹤0.01% | 4620 |
|
|
2024
Q2 | $2.74M | Sell |
60,528
-45,850
| -43% | -$1.93M | ﹤0.01% | 3688 |
|
|
2024
Q1 | $4.17M | Buy |
+106,378
| New | +$2.62M | ﹤0.01% | 3267 |
|
|
2022
Q4 | – | Sell |
-2,953
| Closed | -$15K | – | 6015 |
|
|
2022
Q3 | $15K | Sell |
2,953
-238
| -7% | -$1.68K | ﹤0.01% | 5981 |
|
|
2022
Q2 | $24K | Buy |
+3,191
| New | +$30.8K | ﹤0.01% | 6144 |
|
|
2022
Q1 | – | Sell |
-2,850
| Closed | -$53K | – | 6609 |
|
|
2021
Q4 | $53K | Sell |
2,850
-2,374
| -45% | -$64.3K | ﹤0.01% | 6256 |
|
|
2021
Q3 | $160K | Buy |
5,224
+3,174
| +155% | +$125K | ﹤0.01% | 5794 |
|
|
2021
Q2 | $113K | Sell |
2,050
-5,116
| -71% | -$284K | ﹤0.01% | 5914 |
|
|
2021
Q1 | $423K | Buy |
7,166
+5,139
| +254% | +$338K | ﹤0.01% | 5238 |
|
|
2020
Q4 | $76K | Sell |
2,027
-1,668
| -45% | -$62.4K | ﹤0.01% | 5330 |
|
|
2020
Q3 | $199K | Buy |
3,695
+1,395
| +61% | +$253K | ﹤0.01% | 4915 |
|
|
2020
Q2 | $579K | Sell |
2,300
-106
| -4% | -$21.4K | ﹤0.01% | 4292 |
|
|
2020
Q1 | $378K | Buy |
2,406
+440
| +22% | +$74.4K | ﹤0.01% | 4377 |
|
|
2019
Q4 | $322K | Sell |
1,966
-946
| -32% | -$140K | ﹤0.01% | 4713 |
|
|
2019
Q3 | $425K | Sell |
2,912
-921
| -24% | -$160K | ﹤0.01% | 4517 |
|
|
2019
Q2 | $797K | Sell |
3,833
-2,227
| -37% | -$477K | ﹤0.01% | 4132 |
|
|
2019
Q1 | $1.26M | Buy |
6,060
+560
| +10% | +$124K | ﹤0.01% | 3927 |
|
|
2018
Q4 | $964K | Buy |
5,500
+3,262
| +146% | +$651K | ﹤0.01% | 3990 |
|
|
2018
Q3 | $507K | Buy |
2,238
+322
| +17% | +$52.1K | ﹤0.01% | 4415 |
|
|
2018
Q2 | $290K | Buy |
1,916
+138
| +8% | +$25.1K | ﹤0.01% | 4802 |
|
|
2018
Q1 | $325K | Buy |
1,778
+748
| +73% | +$168K | ﹤0.01% | 4738 |
|
|
2017
Q4 | $219K | Buy |
+1,030
| New | +$220K | ﹤0.01% | 5376 |
|
Other funds holding CRBP
CAM
O
JHC
PM
SCM
ACM
Goldman Sachs's CRBP Position: Q2 2026 in Review
Goldman Sachs reduced its Corbus Pharmaceuticals (CRBP) stake by 32% in Q2 2026, selling an estimated $286K and leaving 62,863 shares worth $590K. The position accounts for ﹤0.01% of the portfolio, ranked #5596.
Goldman Sachs first reported a position in CRBP in Q4 2017 and has held it in 29 quarters since. The position peaked at $4.17M in Q1 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.
- Goldman Sachs held 62,863 shares of Corbus Pharmaceuticals worth $590K as of Q2 2026.
- Goldman Sachs sold 30,248 Corbus Pharmaceuticals shares in Q2 2026, an estimated $286K.
- Corbus Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5596 holding.
- Goldman Sachs first reported a position in Corbus Pharmaceuticals in Q4 2017 and has held it in 29 quarters since.
- Goldman Sachs's Corbus Pharmaceuticals position peaked at $4.17M in Q1 2024.
- 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.